文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

COVID-19 ICU患者的合并感染与ICU获得性感染:UNITE-COVID数据集的二次分析

Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set.
PubMed 文献 · Crit Care · 2022-08-03
一句话结论首波重症COVID-19患者入ICU时细菌合并感染占14%但85%已用抗生素,ICU获得性感染达54%且与使用糖皮质激素相关。

该研究为多中心、国际、观察性研究的二次分析,纳入2020年2月15日至5月15日首波疫情期间ICU收治的PCR确诊COVID-19成年患者4994例。入ICU时细菌合并感染716例(14%),但85%的患者在此阶段接受了抗生素;2715例(54%)发生ICU获得性感染,最常见为细菌性肺炎(占感染的44%),9%的患者发生真菌性肺炎,25%的感染涉及多重耐药菌。倾向性匹配队列中,使用糖皮质激素者71%发生ICU获得性感染,未使用者52%;糖皮质激素疗程亦与ICU获得性感染及多重耐药菌感染相关。

要点

  • 4994例重症COVID-19患者中,入ICU时细菌合并感染716例(14%),而85%在该阶段已接受抗生素,抗生素使用远超该指征。
  • 2715例(54%)发生ICU获得性感染;最常见为细菌性肺炎(占感染的44%),9%发生真菌性肺炎,25%的感染涉及多重耐药菌。
  • 发生ICU获得性感染者抗菌药物暴露高于未发生者;ICU获得性感染发生密度(每1000个ICU日)明显高于大流行前监测报告。
  • 单因素分析中,使用糖皮质激素者58%发生ICU获得性感染,未使用者43%。
  • 倾向性匹配校正混杂后,使用糖皮质激素者71%发生ICU获得性感染,未使用者52%;糖皮质激素疗程与ICU获得性感染及多重耐药菌感染相关。

适用人群与场景

  • 2020年2月15日至5月15日首波COVID-19疫情期间入住ICU的PCR确诊COVID-19成年患者,来自多中心、国际队列。

研究设计与关键结果

  • 研究类型为多中心、国际、观察性研究的二次分析,数据来自4994例患者,入ICU时细菌合并感染716例(14%),85%的患者在该阶段接受抗生素。
  • 2715例(54%)发生ICU获得性感染,最常见为细菌性肺炎(占感染的44%),9%的患者发生真菌性肺炎,25%的感染涉及多重耐药菌。
  • 发生ICU获得性感染者抗菌药物暴露高于未发生者;ICU获得性感染发生密度(每1000个ICU日)明显高于大流行前监测报告。
  • 各ICU间糖皮质激素使用存在异质性;单因素分析中,使用糖皮质激素者58%发生ICU获得性感染,未使用者43%。
  • 倾向性匹配队列校正潜在混杂后,使用糖皮质激素者71%发生ICU获得性感染,未使用者52%。
  • 糖皮质激素疗程与ICU获得性感染的发生及多重耐药菌感染相关。
  • 试验注册:ClinicalTrials.gov NCT04836065(2021年4月8日回顾性注册)。

证据类型、等级与局限

  • 证据类型:多中心、国际、观察性研究的二次分析;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,首波重症COVID-19患者入ICU时合并感染相对少见,但抗生素使用大幅超出该指征。
  • 作者认为,ICU获得性感染常见,且与糖皮质激素使用显著相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The COVID-19 pandemic presented major challenges for critical care facilities worldwide. Infections which develop alongside or subsequent to viral pneumonitis are a challenge under sporadic and pandemic conditions; however, data have suggested that patterns of these differ between COVID-19 and other viral pneumonitides. This secondary analysis aimed to explore patterns of co-infection and intensive care unit-acquired infections (ICU-AI) and the relationship to use of corticosteroids in a large, international cohort of critically ill COVID-19 patients.

METHODS: This is a multicenter, international, observational study, including adult patients with PCR-confirmed COVID-19 diagnosis admitted to ICUs at the peak of wave one of COVID-19 (February 15th to May 15th, 2020). Data collected included investigator-assessed co-infection at ICU admission, infection acquired in ICU, infection with multi-drug resistant organisms (MDRO) and antibiotic use. Frequencies were compared by Pearson's Chi-squared and continuous variables by Mann-Whitney U test. Propensity score matching for variables associated with ICU-acquired infection was undertaken using R library MatchIT using the "full" matching method.

RESULTS: Data were available from 4994 patients. Bacterial co-infection at admission was detected in 716 patients (14%), whilst 85% of patients received antibiotics at that stage. ICU-AI developed in 2715 (54%). The most common ICU-AI was bacterial pneumonia (44% of infections), whilst 9% of patients developed fungal pneumonia; 25% of infections involved MDRO. Patients developing infections in ICU had greater antimicrobial exposure than those without such infections. Incident density (ICU-AI per 1000 ICU days) was in considerable excess of reports from pre-pandemic surveillance. Corticosteroid use was heterogenous between ICUs. In univariate analysis, 58% of patients receiving corticosteroids and 43% of those not receiving steroids developed ICU-AI. Adjusting for potential confounders in the propensity-matched cohort, 71% of patients receiving corticosteroids developed ICU-AI vs 52% of those not receiving corticosteroids. Duration of corticosteroid therapy was also associated with development of ICU-AI and infection with an MDRO.

CONCLUSIONS: In patients with severe COVID-19 in the first wave, co-infection at admission to ICU was relatively rare but antibiotic use was in substantial excess to that indication. ICU-AI were common and were significantly associated with use of corticosteroids. Trial registration ClinicalTrials.gov: NCT04836065 (retrospectively registered April 8th 2021).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Conway Morris A, Kohler K, De Corte T, et al. Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set. Crit Care. 2022. PMID: 35922860. doi:10.1186/s13054-022-04108-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。